**Name of Journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 21103**

**Manuscript Type: Review**

**Hepatitis C virus infection: are there still specific problems with genotype 3?**

Gondeau C *et al.*Outcome of HCV genotype 3 infection

Claire Gondeau, Georges Philippe Pageaux, Dominique Larrey

**Claire Gondeau, Georges Philippe Pageaux, Dominique Larrey**, Department of Hepato-gastroenterology A, Hospital Saint Eloi, CHRU, 34295 Montpellier, France

**Claire Gondeau, Dominique Larrey**, INSERM U1183, Institute of regenerative medicine and biotherapy, University of Montpellier, 34295 Montpellier, France

**Author contributions:** Gondeau C conducted the review of existing research and drafted the manuscript; Pageaux GP and Larrey D edited the final version.

**Supported by** Agence Nationale de la Recherche sur le SIDA et les Hépatites Virales.

**Conflict-of-interest statement:** Gondeau C declare no conflict of interest; Pageaux GP and Larrey D have received fees for serving as speakers and advisory board members for BMS, Gilead, Merck, Janssen. Larrey D has received fees for serving as a speaker and advisory board member for Abbvie.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Claire Gondeau, PhD,** INSERM U1183, Institute of regenerative medicine and biotherapy, University of Montpellier, 34295 Montpellier, France. claire.gondeau@inserm.fr

**Telephone:** +33-4-67330493

**Fax:** +33-4-67330459

**Received:** June 29, 2015

**Peer-review started:** July 3, 2015

**First decision:** July 20, 2015

**Revised:** August 7, 2015

**Accepted:** September 28, 2015

**Article in press:**

**Published online:**

**Abstract**

Hepatitis C virus infection is one of the most common causes of chronic liver disease and the main indication for liver transplantation worldwide. As promising specific treatments have been introduced for genotype 1, clinicians and researchers are now focusing on patients infected by non-genotype 1 hepatitis C viruses, particularly genotype 3. Indeed, in the golden era of direct-acting antiviral drugs, genotype 3 infections are no longer considered as easy to treat and are associated with higher risk of developing severe liver injuries, such as cirrhosis and hepatocellular carcinoma. Moreover, hepatitis C virus (HCV) genotype 3 accounts for 40% of all HCV infections in Asia and is the most frequent genotype among HCV-positive injecting drug users in several countries. Here, we review recent data on HCV genotype 3 infection/treatment, including clinical aspects and the underlying genotype-specific molecular mechanisms.

**Key words:** Hepatitis C; Genotype 3; direct-acting antivirals; Interferon; Hepatocellular carcinoma

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This article reviews the complex relationship between hepatitis C virus (HCV) genotypes and the possible complications in chronically infected patients. We discuss recent updates on the epidemiology and clinical aspects of HCV genotype 3 infection, including the currently available therapies. We also describe model systems to study the HCV genotype-specific molecular mechanisms.

Gondeau C, Pageaux GP, Larrey D. Hepatitis C virus infection: are there still specific problems with genotype 3? *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Currently, about 3% of the world population is infected by the hepatotropic virus responsible for hepatitis C (HCV)[[1](#_ENREF_1)]. Thanks to intense research during the last two decades, HCV life cycle is now well known[[2-4](#_ENREF_2)]. HCV is a small enveloped virus belonging to the *Flaviviridae* family and the hepacivirus genus, with a plus-strand RNA genome of about 9.6 kb. The HCV genome consists of a single open reading frame that encodes a large polyprotein of approximately 3000 amino acids. This polyprotein is processed by host and viral proteases to generate three structural (core, E1, E2) and seven non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B)[[5](#_ENREF_5)]. Due to the error-rate of its RNA-dependent RNA polymerase NS5B, the high levels of viral replication and the pressure exerted by the host immune response, HCV sequence is highly variable, resulting in its classification in seven genotypes (GT) and 67 subtypes[[6](#_ENREF_6)].

Two recent studies estimated the global burden of HCV infection and genotype distribution[[7](#_ENREF_7),[8](#_ENREF_8)]. GT-1 is the most prevalent worldwide (46%), followed by GT-3 (22%). HCV genotype distribution shows geographic variations that reflect transmission mode differences and ethnic variability. Genotype diversity also directly affects the infected patients’ outcome due to genotype-specific differences in response to treatment and disease severity. Until recently, HCV GT-3 was considered to be an easy-to-treat infection by using the standard combination of pegylated interferon  (PEG-IFN) and ribavirin (RBV), with higher cure rates (about 70%) than the other viral genotypes (particularly GT-1)[[9](#_ENREF_9)]. In 2011, the approval of the first HCV protease inhibitors, in combination with PEG-IFN and RBV, greatly improved the treatment of HCV GT-1 in Europe and the United States. However, due to the side effect profiles and costs per sustained virologic response (SVR), this triple combination is no longer recommended by the European Association for the Study of the Liver (EASL recommendations 2015[[10](#_ENREF_10)]). Indeed, several more effective and better tolerated direct-acting antivirals (DAAs) are now in clinical development[[11](#_ENREF_11)], or have been approved by the Food and Drug Administration (FDA) and the European Medical Agency (EMA). Among them, a nucleotide analog inhibitor of the HCV RNA-dependent RNA polymerase (sofosbuvir), a second-generation protease inhibitor (simeprevir) and two HCV-NS5A inhibitors (daclatasvir and ledipasvir) can be used in combination therapies.

Despite the wide range of new DDAs, few therapeutic options are effective for HCV GT-3. Moreover, the high cost of the new treatments implies a careful patient selection and will limit treatment delivery in some regions of the world. Here, we discuss the specific features and current issues of HCV GT-3 infection/treatment, including clinical aspects and the underlying molecular mechanisms.

**EPIDEMIOLOGY**

#### Although persistent HCV infection is one of the leading causes of liver-related morbidity and mortality, possibly accounting for up to 0.5 million deaths every year[[12](#_ENREF_12)], its epidemiology remains poorly understood in many countries. As the efficacy of current and new therapies differ according to the HCV genotype, epidemiological data on the infected populations and the HCV genotype distribution have important clinical implications. Several recent studies on the global, regional and national prevalence and genotype distribution of HCV infection highlighted significant geographical differences[[7](#_ENREF_7),[13-15](#_ENREF_13)] (summarized in Table 1). Specifically, HCV GT-3 accounts for 40% of all HCV infections in Asia, with a high prevalence in India, Malaysia and Pakistan (54%, 59% and 79%, respectively)[[8](#_ENREF_8)]. HCV GT-3 is also predominant (> 43%) in some European countries (Denmark, Finland and United Kingdom) and might represent 50% of all HCV infections in Norway[[14](#_ENREF_14)] and about 36% in Australasia[[8](#_ENREF_8)]. The genotype distribution in a country may change from one year to the other, partly due to the migration of infected individuals and therefore, needs to be regularly updated. For instance, a recent study conducted in the southern part of Turkey reported a HCV GT-3 prevalence of 46%, a rate remarkably higher than that from previous Turkish findings[[16](#_ENREF_16)] (Table 1). Updated data from **four regions of Thailand and from Southeast Asia also indicate variations in the** d**istribution of HCV genotypes and subtypes, notably in the 3a/3b subtype ratio**[[17](#_ENREF_17)] (Table 1). Phylogenetic analysis of HCV subtype 3a, the prevalent subtype in Thailand, showed that the genotypes of HCV samples from infected Thai and Indian/Pakistani patients cluster in close proximity, supporting the hypothesis of a close relationship between the HCV subtype 3a viruses that circulate in these countries[[18](#_ENREF_18)].

Over the last ten years, GT-3 was reported as the most frequent genotype among HCV-positive injecting drug users (IDUs) in several countries[[19-21](#_ENREF_19)]. In 2011, Nelson *et al*[[22](#_ENREF_22)] performed a global systematic review of HCV prevalence among IDUs and found that about 10 million IDUs worldwide might be HCV-positive. China, the United States and the Russian Federation have by far the largest HCV-positive IDU populations. Thus, IDUs are now at the heart of the HCV epidemics in developed countries[[23](#_ENREF_23),[24](#_ENREF_24)]. More specifically, HCV subtype 3a, which originated from Asia, has spread widely among IDUs and also among other patient groups in industrialized countries[[25](#_ENREF_25)]. Recently, a prospective, multicenter cohort study on the treatment of HCV/HIV-positive patients after liver transplantation in Spain indicated that co-infected patients were younger and had more frequently HCV GT-3 than patients infected only by HCV[[26](#_ENREF_26)].

**CLINICAL COURSE**

***pathologies frequently associated with hcv genotype 3***

Most HCV infections are asymptomatic. Consequently, infected individuals are not aware of their illness until the appearance of severe and irreversible liver disease, often several decades after the initial infection. Steatosis, characterized by lipid droplet accumulation in the cytoplasm of hepatocytes, is an extremely common histological finding in patients with chronic HCV (from approximately 40% to 80%, depending on the studies) and its prevalence is two times higher than in the general population[[27](#_ENREF_27)][Smith, 2014 #514]. Several risk factors for steatosis and liver injuries in HCV infection (*i.e.*, high fat diet, chronic alcohol consumption, dyslipidemia, obesity, chronic drug consumption, diabetes, insulin resistance, *etc.*) are the same as for alcoholic and non-alcoholic steatohepatitis, thus rendering the precise relationship between steatosis and HCV difficult to determine[[28](#_ENREF_28),[29](#_ENREF_29)]. Nevertheless, in 1997, a study on the liver histopathological lesions in 90 HCV-positive patients revealed a significantly higher prevalence of steatosis among patients infected by HCV GT-3a than by GT-1a or 1b[[30](#_ENREF_30)]. Since then, several other works confirmed this association and provided evidence of a HCV GT-3-specific cytopathic effect[[31](#_ENREF_31),[32](#_ENREF_32)]. In a later study, Rodriguez-Torres *et al*[[33](#_ENREF_33)] reported that among 614 patients, those with HCV GT-3 infection were more likely to have steatosis than patients infected by HCV GT-2 (79% *vs* 59%). This HCV genotype was qualified as steatogenic. Indeed, several studies reported a significant improvement in steatosis in HCV GT-3 patients who achieved sustained viral clearance after antiviral therapy[[34-36](#_ENREF_34)], Furthermore, GT-3 patients tend to have hypocholesterolemia and hypobetalipoproteinemia[[37-39](#_ENREF_37)], thus accounting for a direct effect of the virus on lipid metabolism. HCV GT-3 infection also promotes liver fibrosis development/progression[[40-43](#_ENREF_40)]. However, the coexistence of host and viral factors contributing to liver steatosis and fibrosis in the same patient impair the analysis of their independent involvement and this issue remains controversial[[44](#_ENREF_44),[45](#_ENREF_45)].

Moreover, chronic HCV induces multiple defects in the upstream components of the insulin signaling pathway in the liver, thus contributing to the observed prevalence of insulin resistance (IR) and type 2 diabetes mellitus in infected patients[[46-48](#_ENREF_46)]. A genotype-specific association between IR and HCV was recently confirmed in a study on 497 HCV GT-1-positive patients and 541 GT-2/3-positive patients who received IFN-based therapy and in whom IR was measured before and 12 weeks after the treatment using the homeostasis model assessment of IR (HOMA-IR)[[49](#_ENREF_49)]. SVR was associated with a reduction in the HOMA-IR value in HCV GT-1-positive patients, but not in those with HCV GT-2 or GT-3 infection. Of note, IR was identified as an independent predictor of advanced fibrosis in patients with chronic HCV GT-3 infection[[45](#_ENREF_45)]. However, the mechanism of HCV-mediated IR and the genotype-specific association remains unclear**.**

Evidence that viral factors, such as the HCV genotype, may affect the risk of progression to cirrhosis or to hepatocellular carcinoma (HCC) is scarce. Larsen *et al*[[50](#_ENREF_50)] investigated the risk factors for these severe liver diseases in HCV-infected drug abusers in France between 2001 and 2007 and showed that HCV GT-3 infection is associated with severe liver disease in drug abusers, independently of age, sex, duration of infection, alcohol consumption and co-infection with HIV. In 2011, Nkontchou *et al*[[51](#_ENREF_51)] reported the association of HCV GT-3 infection and higher HCC incidence in patients with cirrhosis in France. A strong association between chronic HCV GT-3a infection and HCC was also found in Pakistan[[52](#_ENREF_52)]. This finding was recently confirmed by the analysis of patients’ data from the Veterans Affairs HCV clinical registry showing that the risks of cirrhosis and HCC were significantly higher in HCV GT-3- than in GT-1-infected patients[[53](#_ENREF_53)].

Conversely, HCV GT-3 was not reported as a significant factor influencing post-liver transplantation hepatitis, contrary to HCV GT-1, although the genotype influence on HCV recurrence after liver transplantation remains controversial[[54](#_ENREF_54)].

***Extra-hepatic manifestations***

Besides liver disease, HCV infection can also cause a variety of extra-hepatic problems (autoimmune and/or lymphoproliferative disorders as well as cardiovascular, renal, metabolic and central nervous system diseases) in up to 74% of patients[[55](#_ENREF_55)]. To the best of our knowledge, there is no evidence of a significant association between extra-hepatic diseases and HCV genotype.

**HCV GENOTYPE 3 AND RESPONSE TO THE STANDARD TREATMENT**

High SVR rates are observed in HCV GT-3-infected patients who receive the standard-of-care treatment (PEG-IFN/RVB). Accordingly, this genotype has been considered as “easy to cure” and grouped with GT-2 in clinical studies. However, increasing evidence indicates that differently from GT-2, some patients infected by HCV GT-3 respond poorly. Several viral or host factors could be associated with this reduced response (summarized in Table 2).

***Viral factors***

The baseline viral load is critical for treatment outcome. Indeed, HCV GT-3-infected patients with high pre-treatment viral load (> 8 × 105 IU/mL) are unlikely to show an SVR[[56](#_ENREF_56)]. Moreover, it is well known that the high degree of genetic diversity of the HCV genome is associated with viral sensitivity or resistance to IFN-based therapy[[57](#_ENREF_57)]. Accordingly, high HCV quasi-species complexity/diversity might negatively influence the outcome of IFN-based therapy in patients with chronic HCV GT-3 infection[[58](#_ENREF_58)]. Viral genetic polymorphisms, especially within the non-structural 5A protein (NS5A) regions, may also be involved in the response to PEG-IFN/RVB therapy[[57](#_ENREF_57),[59-61](#_ENREF_59)]. Specifically, in a small cohort of 49 non-responder and responder HCV GT-3a-infected patients, Mansoor *et al*[[62](#_ENREF_62)] identified NS5A mutations that allow predicting the response to treatment.

***Host factors***

Several studies suggest that liver fibrosis and cirrhosis have a negative effect on the treatment response in HCV GT-3-infected patients[[63](#_ENREF_63),[64](#_ENREF_64)] and that they are associated with an increased risk of hepatitis relapse after treatment[[63](#_ENREF_63)]. Recently, a multicenter, open- label, randomized trial (*n =* 136 patients) showed that patients infected by HCV GT-3 and with advanced fibrosis do not benefit from extended therapy (48 weeks) with PEG-INF/RBV[[65](#_ENREF_65)]. Moreover, in a small cohort of 180 Canadian patients, Powis *et al*[[66](#_ENREF_66)] found a significant interaction between cirrhosis and HCV GT-3 (*vs* GT-2), leading to poor antiviral response. However, this association was also reported for other genotypes[[67](#_ENREF_67)].

Among the severe liver injuries linked to HCV, steatosis negatively influences the response to antiviral therapy[[68](#_ENREF_68)], particularly in HCV GT-3-infected patients[[69](#_ENREF_69)], and is an independent predictor of relapse after rapid virologic response in these patients, irrespectively of the viral load[[70](#_ENREF_70)]. However, using the database of a large prospective clinical trial in patients with HCV GT-2 or GT-3 infection, Rodriguez-Torrez *et al*[[33](#_ENREF_33)] found that liver steatosis did not affect the viral response in patients treated with PEG-IFN/RBV for 16 or 24 wk. A major limitation of many studies on SVR predictors is that they evaluated HCV GT-2- and GT-3-infected patients together. Therefore, Marciano *et al*[[71](#_ENREF_71)] performed a retrospective multicenter study on 107 HCV GT-3-infected patients in Argentina and showed that advanced fibrosis and high pre-treatment viral load were associated with poor response to PEG-IFN/RBV in the patients who did not achieve an SVR.

Several studies focused on ethnic features that may influence the efficacy of IFN-based therapy, mainly by comparing Asian and Caucasian patients[[72](#_ENREF_72),[73](#_ENREF_73)]. In 2008, a small study found a lower SVR rate in South Asian patients infected by HCV GT-3 than in Caucasians[[74](#_ENREF_74)]. The influence of Asian ethnicity on the response to therapy for HCV GT-3 infection appears to be a major issue because this HCV genotype accounts for 40% of all infections in Asia. However, this association remains controversial because a retrospective analysis of 604 patients infected by HCV GT-3 and undergoing therapy in four United Kingdom centers (where many patients originate from the Indian subcontinent) showed that the response to antiviral therapy was affected by age, cirrhosis and diabetes, but not by the patient ethnicity (South Asian *vs* Caucasian)[[64](#_ENREF_64)].

Polymorphisms of the interleukin-28B gene (*IL28B*, also named *IFNL3* for IFN lambda 3) located on chromosome 19 may affect both the natural history of HCV infection and the patient response to IFN-based therapy[[75](#_ENREF_75),[76](#_ENREF_76)]. A recent systematic meta-analysis revealed a weak correlation between treatment outcome and IFNL3 genotype in patients infected by HCV GT-3 or GT-2[[77](#_ENREF_77)]. However, in most studies analyzed in this review, these two genotypes were included in the same subgroup, thus rendering difficult to draw conclusions exclusively for GT-3. The recent study by Marciano *et al*[[71](#_ENREF_71)] on 107 HCV GT-3-infected patients in Argentina did not find any association between *IFNL3* polymorphisms and SVR, while a study on HCV GT-3 infected patients in India showed that two favorable single nucleotide polymorphisms (SNPs) (rs12979860 and rs8099917) are strongly associated with SVR[[78](#_ENREF_78)]. Holmes *et al*[[79](#_ENREF_79)] evaluated the association between *IFNL3* and *IFNL4* (a variant upstream of *IFNL3* identified as a new IFNL gene[[80](#_ENREF_80)]) genotypes, intrahepatic expression of IFN-stimulated genes (ISGs) and PEG-IFN/RBV treatment outcome in HCV GT-1 and GT-3-infected patients. Interestingly, this retrospective analysis of 259 patients treated with PEG-IFN/RBV in a single large tertiary center in Australia between 2004 and 2011 clearly highlights fundamental differences in the host response to HCV GT-1 and GT-3 infection, with a central role for intrahepatic ISG15 expression, independently of the IFNL4 genotype. The lowest ISG15 level was observed in HCV GT-3-infected patients with the good-responder *IFNL4* genotype and the highest SVR. Conversely, the highest ISG15 level was detected in HCV GT-1-infected patients with the poor-responder *IFNL4* genotype and the lowest SVR rates. Robinson *et al*[[81](#_ENREF_81)] compared gene transcription profiles in liver biopsies from uninfected and HCV GT-1- or GT-3-infected patients and confirmed the reduced predictive value of the *IFNL* genotype for HCV GT-3. Moreover, investigation of the host-pathogen interactions that underlie the genotype-specific clinical outcomes of chronic HCV infection[[82](#_ENREF_82)] showed elevated ISG transcription in peripheral blood mononuclear cells from HCV GT-1-, but not from GT-3-infected patients, thus confirming the genotype-specific host-pathogen interactions.

***HCV GT-3 infection after liver transplantation***

Until recently, the treatment outcome of recurrent HCV GT-3 infection after liver transplantation was not precisely known. Faisal *et al*[[83](#_ENREF_83)] demonstrated that the efficacy of the PEG-IFN/RBV combination for recurrent HCV GT-3 infection after liver transplantation is high and comparable with that in non-transplanted patients.

To improve the virologic response to IFN therapy, some combinations with other drugs were assessed. For instance, a case report indicated that the association of PEG-IFN/RBV and silibinin (an antiviral drug) resulted in an SVR after 24 wk in a treatment-naive patient who was reinfected by HCV GT-3 after liver transplantation[[84](#_ENREF_84)].

Other drugs have been tested in combination with PEG-IFN and RBV. A prospective study on 179 treatment-naive patients with chronic HCV GT-1 or GT-3 infection indicated that fluvastatin (a 3-hydroxyl-3-methylglutaryl-coenzyme A reductase inhibitor of the statin family) combined with PEG-IFN/RBV improves the SVR in naive patients chronically infected by HCV GT-1 and high viral load, but not in patients infected by HCV GT-3[[85](#_ENREF_85)]. Similarly, no significant benefit of statin in HCV GT-3 infection was found in a study based on the analysis of the US Department of Veterans Affairs patient database[[86](#_ENREF_86)].

# Finally, severe side effects have been reported during IFN therapy and are one of the most frequent causes of treatment discontinuation[[87](#_ENREF_87),[88](#_ENREF_88)]. Moreover, in specific groups of patients, IFN-based regimens are contraindicated or not applicable or failed repeatedly. Therefore, IFN-free regimens need to be developed/tested in these patients.

**GENOTYPE 3 IN DAA GOLDEN ERA**

Until 2013 and given the relative efficacy of the standard-of-care treatment (PEG-IFN and RBV for 24 wk) for the other genotypes, research and drug development focused mainly on HCV GT-1. Currently, the introduction of DAAs has revolutionized HCV GT-1 therapy, while few effective treatment options are available for patients infected by HCV GT-3 who do not achieve an SVR with IFN (particularly, patients with cirrhosis), or have medical contraindications to IFN. First-generation, first wave NS3/4A protease inhibitors (telaprevir and boceprevir) are not efficient against HCV GT-3 infection[[11](#_ENREF_11),[89](#_ENREF_89),[90](#_ENREF_90)]. For instance, Foster *et al*[[89](#_ENREF_89)] reported that telaprevir alone or with PEG-IFN and RBV reduces the plasma levels of HCV RNA in patients with chronic HCV GT-2, but not GT-3 infection. Similarly, second-wave protease inhibitors, such as simeprevir (TMC435), are active against several HCV genotypes, but not GT-3[[91](#_ENREF_91),[92](#_ENREF_92)]. The second generation of NS3-4A protease inhibitors, such as MK-5172[[93](#_ENREF_93)], was developed to overcome the major limitations of first-generation antiviral drugs (*i.e.,* low barriers to resistance, dosing, clinically challenging side-effects and lack of pan-genotype activity)[[94](#_ENREF_94)]. However, these drugs also are not effective against HCV GT-3 infection.

Therefore, despite the wide range of potent antiviral drugs, therapies approved in the United States and Europe for the treatment of HCV GT-3 infection include only two pan-genotypic DAAs that target key proteins in HCV replication: the first-generation NS5A inhibitor daclatasvir (DCV)[[95](#_ENREF_95)] and sofosbuvir (SOF), a nucleotide analogue targeting the NS5B polymerase[[96](#_ENREF_96)]. Currently, SOF is considered to be the backbone for the treatment of HCV GT-2-4 infections. These IFN-free, all-oral treatments are attractive, especially to avoid the many IFN-induced adverse effects. Nevertheless, the treatment choice mainly depends on the liver fibrosis stage and on the previous therapies. In April 2015, the EASL Clinical Practice Guidelines[[10](#_ENREF_10)] recommended only three treatment options with DAAs for HCV GT-3 infections, in addition to PEG-IFN/RBV, and two of them are IFN-free regimens (summarized in Table 3).

***IFN-containing treatments***

A combination of PEG-IFN once per week and daily RBV and SOF for 12 weeks can be used. Indeed, a phase II clinical trial on 47 HCV GT-2 or GT-3 patients showed that this regimen gives high SVR rates in treatment-experienced patients with HCV GT-3 infection, irrespective of their cirrhosis status, and is well tolerated[[97](#_ENREF_97)]. Although not recommended yet by the EASL in May 2015, other combinations were recently tested in clinical trials. Notably, the treatment duration with PEG-IFN/RBV could be reduced to 12 or 16 wk when combined with DCV in HCV GT-3- infected patients[[98](#_ENREF_98)].

***IFN-free treatments***

For patients for whom IFN is not an option (*i.e.,* who do not have an SVR with the 24-wk PEG-IFN/RBV treatment, and for patients with medical contraindications), only two IFN-free regimens could be efficient. Again, clear differences were highlighted when HCV GT-3 and GT-2-infected patients were compared. For instance, two randomized, phase III clinical trials (FUSION and POSITRON)[[99](#_ENREF_99)] reported the need to extend the duration of the SOF/RBV treatment to 16 weeks for HCV GT-3 infection, particularly in cirrhotic or treatment-experienced patients, to obtain a high response rate. Conversely, 12 wk were sufficient to achieve an SVR in HCV GT-2-infected patients. In the VALENCE study[[100](#_ENREF_100)], therapy with SOF/RBV was extended to 24 wk for HCV GT-3-infected patients (compared to 12 wk in HCV GT-2-infected patients), resulting in high SVR rates. However, this combination was suboptimal for treatment-experienced cirrhotic patients.

The second IFN-free regimen that gives satisfying results for GT-3 patients is the combination of SOF and DCV for 12 wk, but only in non-cirrhotic patients. Indeed, in the ALLY-3 phase III clinical trial in treatment-naive (*n =* 101) or treatment-experienced (*n =* 51) HCV GT-3 patients, an SVR was achieved in 96% of patients without cirrhosis after 12 wk of well-tolerated treatment, while only 58% of cirrhotic patients achieved an SVR[[101](#_ENREF_101)]. Similar results were reported by a French multicenter study on the compassionate use of SOF/DCV ± RBV in patients with HCV GT-3[[102](#_ENREF_102)]. A regimen with a single tablet that contains ledipasvir and SOF (the two first-generation NS5A inhibitors) was recently approved in the United States and Europe and represents a significant advance for HCV treatment[[103](#_ENREF_103)]. However, published studies are lacking on its use for HCV GT-3 treatment. Based on the few available data[[104](#_ENREF_104)] and on the low *in vitro* efficacy of ledipasvir on NS5A activity[[105](#_ENREF_105)], this combination is not recommended yet by the EASL in May 2015[[10](#_ENREF_10)]. Among the many combinations tested to date, Gane *et al*[[106](#_ENREF_106)] recently reported results from a phase II pilot study that assessed the safety and efficacy of RBV combined with grazoprevir and elbasvir (two potent NS3/4 and NSA5 inhibitors, respectively) in treatment-naive, non-cirrhotic patients with HCV GT-3 infection. This combination was poorly efficient in this population.

Overall, the available data suggest that subgroups of patients infected by HCV GT-3, particularly those with advanced liver fibrosis or a previous failure of IFN-based therapy, are more difficult to cure with the short IFN-free regimens available in 2015. As achieving an undetectable viral load is associated with decreased hepatic morbidity and mortality[[53](#_ENREF_53)], it is critical to improve the treatment for these subgroups of patients. Among the currently evaluated DAAs that are active against GT-3, the pangenotypic NS5A inhibitor GS-5816, combined with SOF ± RBV is a promising therapeutic option[[107](#_ENREF_107),[108](#_ENREF_108)].

**GENOTYPE 3 AND STUDY MODELS**

Following the description of the association between HCV GT-3 infection and lipid accumulation in the liver in clinical studies, much effort has been made to understand the HCV genotype-specific pathogenic mechanisms. Detailed discussions of the different proposed molecular mechanisms are reviewed elsewhere and highlight the difficulties to identify pathological hallmarks of HCV GT-3 infection both in *in vitro* and *in vivo* models[[109](#_ENREF_109),[110](#_ENREF_110)].

Several evidences of perturbations induced specifically by HCV GT-3 infection, particularly the deregulation of lipoprotein metabolism, were obtained by analyzing liver biopsies and plasma samples from chronically infected patients[[111-114](#_ENREF_111)]. As liver damage may be multifactorial, the major challenge in clinical research studies is to carefully exclude patients with risk factors for liver steatosis other than HCV (*i.e.*, patients with obesity, significant alcohol intake, diabetes, ongoing intravenous drug addiction, or use of steatogenic drugs).

In the last decade, it was suggested that the viral capsid core protein has a central and genotype-specific role. However, this hypothesis remains controversial[[109](#_ENREF_109)]. Indeed, our current understanding of HCV GT-3 effects is largely based on studies using the human hepatoma Huh7 cell line that expresses the HCV GT-1b or GT-3a core protein[[114-116](#_ENREF_114)]. However, these cell models do not mimic the liver physiological reality and complexity, or the viral infection processes and the specific intrinsic functions of other HCV GT-3 proteins.

Since 2005, a unique cell culture system based on the HCV GT-2a clone JFH1 and chimeric constructs allows the efficient replication of HCV and the *de novo* production of viral particles *in vitro* (HCVcc)[[117](#_ENREF_117)]. Recently, we demonstrated that in well-defined culture conditions, adult primary human hepatocytes (PHH), isolated from liver tissue, support the complete infection cycle of natural HCV from patients’ serum samples[[118](#_ENREF_118)]. By testing the *in vitro* infectivity of about 120 HCV-positive serum samples in PHH cultures, we identified the highly infectious HCV GT-3a strain S310. We then cloned the full-length consensus genomic sequence of S310 and constructed a subgenomic replicon, thus providing a new tool to study HCV GT-3a replication in Huh-7 cells[[119](#_ENREF_119)]. We also identified critical mutations in subgenomic replicons that strongly promote viral replication and that were subsequently introduced in the full-length S310 HCV RNA. Kim *et al*[[120](#_ENREF_120)] then demonstrated that full-length S310 clones replicate efficiently and produce infectious viral particles (HCVcc/S310) in Huh-7 cells, thus providing an unique infectious HCV GT-3a cell system. Interestingly, differences in HCV core protein localization and lipid content were observed in S310 (GT-3a)-infected and JFH1 (GT-2a)-infected cells. Moreover, the protease inhibitor telaprevir is less effective against S310- than JFH1-infected cells, as reported in the clinic.

Therefore, HCVcc/S310 particles represent a promising tool to determine the precise pathogenesis of HCV GT-3 infection and to understand the reasons of the effectiveness variations of different antiviral drugs. Further work is now needed to combine this HCV GT-3 strain with the most relevant host cell systems, such as primary cells, mouse models[[121](#_ENREF_121)] or systems derived from tissue engineering[[122](#_ENREF_122)].

**CONCLUSION**

Better understanding chronic HCV infection and the determinants of the treatment outcome appears nowadays as a key challenge. During the last few years, clinical research investigated mainly the interactions between viral and host factors, especially in HCV GT-3 infection. This genotype is significantly associated with severe liver disease and low response to most of the currently approved DAAs. The association of HCV GT-3 infection with the highest risk of cirrhosis and HCC underscores the medical need for safe and effective treatment options for patients infected by HCV with this genotype. Luckily, recent clinical and basic research studies have been focusing more on HCV GT-3, in order to develop new strategies for providing timely and effective care for this high-risk population. Among the antiviral drugs under evaluation, host-targeted antivirals, like cyclophilin inhibitors, may be of great interest within the next few years.

**REFERENCES**

1 **Thomas DL**. Global control of hepatitis C: where challenge meets opportunity. *Nat Med* 2013; **19**: 850-858 [PMID: 23836235 DOI: 10.1038/nm.3184]

2 **Lohmann V**. Hepatitis C virus RNA replication. *Curr Top Microbiol Immunol* 2013; **369**: 167-198 [PMID: 23463201 DOI: 10.1007/978-3-642-27340-7\_7]

3 **Niepmann M**. Hepatitis C virus RNA translation. *Curr Top Microbiol Immunol* 2013; **369**: 143-166 [PMID: 23463200 DOI: 10.1007/978-3-642-27340-7\_6]

4 **Zeisel MB**, Felmlee DJ, Baumert TF. Hepatitis C virus entry. *Curr Top Microbiol Immunol* 2013; **369**: 87-112 [PMID: 23463198 DOI: 10.1007/978-3-642-27340-7\_4]

5 **Moradpour D**, Penin F, Rice CM. Replication of hepatitis C virus. *Nat Rev Microbiol* 2007; **5**: 453-463 [PMID: 17487147 DOI: 10.1038/nrmicro1645]

6 **Smith DB**, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. *Hepatology* 2014; **59**: 318-327 [PMID: 24115039 DOI: 10.1002/hep.26744]

7 **Wedemeyer H**, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide - filling the gaps. *J Viral Hepat* 2015; **22** Suppl 1: 1-5 [PMID: 25560838 DOI: 10.1111/jvh.12371]

8 **Gower E**, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. *J Hepatol* 2014; **61**: S45-S57 [PMID: 25086286 DOI: 10.1016/j.jhep.2014.07.027]

9 **Pawlotsky JM**, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. *J Hepatol* 2015; **62**: S87-S99 [PMID: 25920094 DOI: 10.1016/j.jhep.2015.02.006]

10 **European Association for Study of Liver**. EASL Recommendations on Treatment of Hepatitis C 2015. *J Hepatol* 2015; **63**: 199-236 [PMID: 25911336 DOI: 10.1016/j.jhep.2015.03.025]

11 **Wendt A**, Adhoute X, Castellani P, Oules V, Ansaldi C, Benali S, Bourlière M. Chronic hepatitis C: future treatment. *Clin Pharmacol* 2014; **6**: 1-17 [PMID: 24470777 DOI: 10.2147/CPAA.S30338]

12 **Lozano R**, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; **380**: 2095-2128 [PMID: 23245604 DOI: 10.1016/S0140-6736(12)61728-0]

13 **Hatzakis A**, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, Schréter I, Baatarkhuu O, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Arkkila P, Barclay K, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Cisneros L, Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D, de Knegt RJ, de Vree M, Estes C, Flisiak R, Gane E, Gower E, Halota W, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kershenobich D, Kostrzewska K, Kristian P, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Norris S, Nurmukhametova E, Nymadawa P, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prabdial-Sing N, Prins M, Radke S, Rakhmanova A, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V, Seguin-Devaux C, Shah SR, Shestakova I, Shevaldin A, Shibolet O, Silva MO, Sokolov S, Sonderup M, Souliotis K, Spearman CW, Staub T, Stedman C, Strebkova EA, Struck D, Sypsa V, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuckerman E, Zuure FR, Puri P, Razavi H. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2. *J Viral Hepat* 2015; **22** Suppl 1: 26-45 [PMID: 25560840 DOI: 10.1111/jvh.12351]

14 **Saraswat V**, Norris S, de Knegt RJ, Sanchez Avila JF, Sonderup M, Zuckerman E, Arkkila P, Stedman C, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin C, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Chulanov V, Cisneros L, Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D, de Vree M, Estes C, Flisiak R, Gadano AC, Gane E, Halota W, Hatzakis A, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kershenobich D, Kostrzewska K, Kristian P, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Mossong J, Nurmukhametova E, Nymadawa P, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prabdial-Sing N, Prins M, Puri P, Radke S, Rakhmanova A, Razavi H, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanduijav R, Schréter I, Seguin-Devaux C, Shah SR, Shestakova I, Shevaldin A, Shibolet O, Sokolov S, Souliotis K, Spearman CW, Staub T, Strebkova EA, Struck D, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuure FR, Silva MO, Sypsa V, Gower E. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2. *J Viral Hepat* 2015; **22** Suppl 1: 6-25 [PMID: 25560839 DOI: 10.1111/jvh.12350]

15 **Messina JP**, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology* 2015; **61**: 77-87 [PMID: 25069599 DOI: 10.1002/hep.27259]

16 **Caliskan A**, Kirisci O, Ozkaya E, Ozden S, Tumer S, Caglar S, Guler SA, Senol H. Distribution and predominance of genotype 3 in hepatitis C virus carriers in the province of kahramanmaras, Turkey. *Hepat Mon* 2015; **15**: e25142 [PMID: 25972903 DOI: 10.5812/hepatmon.15(4)2015.25142]

17 **Wasitthankasem R**, Vongpunsawad S, Siripon N, Suya C, Chulothok P, Chaiear K, Rujirojindakul P, Kanjana S, Theamboonlers A, Tangkijvanich P, Poovorawan Y. Genotypic distribution of hepatitis C virus in Thailand and Southeast Asia. *PLoS One* 2015; **10**: e0126764 [PMID: 25962112 DOI: 10.1371/journal.pone.0126764]

18 **Akkarathamrongsin S**, Hacharoen P, Tangkijvanich P, Theamboonlers A, Tanaka Y, Mizokami M, Poovorawan Y. Molecular epidemiology and genetic history of hepatitis C virus subtype 3a infection in Thailand. *Intervirology* 2013; **56**: 284-294 [PMID: 23838334 DOI: 10.1159/000351621]

19 **Payan C**, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, Trimoulet P, Couzigou P, Cointe D, Chaput C, Henquell C, Abergel A, Pawlotsky JM, Hezode C, Coudé M, Blanchi A, Alain S, Loustaud-Ratti V, Chevallier P, Trepo C, Gerolami V, Portal I, Halfon P, Bourlière M, Bogard M, Plouvier E, Laffont C, Agius G, Silvain C, Brodard V, Thiefin G, Buffet-Janvresse C, Riachi G, Grattard F, Bourlet T, Stoll-Keller F, Doffoel M, Izopet J, Barange K, Martinot-Peignoux M, Branger M, Rosenberg A, Sogni P, Chaix ML, Pol S, Thibault V, Opolon P, Charrois A, Serfaty L, Fouqueray B, Grange JD, Lefrère JJ, Lunel-Fabiani F. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. *J Viral Hepat* 2005; **12**: 405-413 [PMID: 15985012 DOI: 10.1111/j.1365-2893.2005.00605.x]

20 **Mahfoud Z**, Kassak K, Kreidieh K, Shamra S, Ramia S. Distribution of hepatitis C virus genotypes among injecting drug users in Lebanon. *Virol J* 2010; **7**: 96 [PMID: 20465784 DOI: 10.1186/1743-422X-7-96]

21 **Samimi-Rad K**, Nasiri Toosi M, Masoudi-Nejad A, Najafi A, Rahimnia R, Asgari F, Shabestari AN, Hassanpour G, Alavian SM, Asgari F. Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time. *Arch Virol* 2012; **157**: 1959-1965 [PMID: 22695769 DOI: 10.1007/s00705-012-1369-9]

22 **Nelson PK**, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. *Lancet* 2011; **378**: 571-583 [PMID: 21802134 DOI: 10.1016/S0140-6736(11)61097-0]

23 **El-Ghitany EM**, Abdel Wahab MM, Abd El-Wahab EW, Hassouna S, Farghaly AG. A comprehensive hepatitis C virus risk factors meta-analysis (1989-2013): do they differ in Egypt? *Liver Int* 2015; **35**: 489-501 [PMID: 24923487 DOI: 10.1111/liv.12617]

24 **Alter MJ**. HCV routes of transmission: what goes around comes around. *Semin Liver Dis* 2011; **31**: 340-346 [PMID: 22189974 DOI: 10.1055/s-0031-1297923]

25 **Morice Y**, Cantaloube JF, Beaucourt S, Barbotte L, De Gendt S, Goncales FL, Butterworth L, Cooksley G, Gish RG, Beaugrand M, Fay F, Fay O, Gonzalez JE, Martins RM, Dhumeaux D, Vanderborght B, Stuyver L, Sablon E, de Lamballerie X, Pawlotsky JM. Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. *J Med Virol* 2006; **78**: 1296-1303 [PMID: 16927280 DOI: 10.1002/jmv.20692]

26 **Castells L**, Rimola A, Manzardo C, Valdivieso A, Montero JL, Barcena R, Abradelo M, Xiol X, Aguilera V, Salcedo M, Rodriguez M, Bernal C, Suarez F, Antela A, Olivares S, Del Campo S, Laguno M, Fernandez JR, de la Rosa G, Agüero F, Perez I, González-García J, Esteban-Mur JI, Miro JM. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. *J Hepatol* 2015; **62**: 92-100 [PMID: 25127748 DOI: 10.1016/j.jhep.2014.07.034]

27 **Hwang SJ**, Lee SD. Hepatic steatosis and hepatitis C: Still unhappy bedfellows? *J Gastroenterol Hepatol* 2011; **26** Suppl 1: 96-101 [PMID: 21199519 DOI: 10.1111/j.1440-1746.2010.06542.x]

28 **Monto A**, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. *Hepatology* 2002; **36**: 729-736 [PMID: 12198667 DOI: 10.1053/jhep.2002.35064]

29 **Irimia E**, Mogoantă L, Predescu IO, Efrem IC, Stănescu C, Streba LA, Georgescu AM. Liver steatosis associated with chronic hepatitis C. *Rom J Morphol Embryol* 2014; **55**: 351-356 [PMID: 24969985]

30 **Mihm S**, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. *Hepatology* 1997; **25**: 735-739 [PMID: 9049227 DOI: 10.1002/hep.510250340]

31 **Rubbia-Brandt L**, Quadri R, Abid K, Giostra E, Malé PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. *J Hepatol* 2000; **33**: 106-115 [PMID: 10905593]

32 **Leandro G**, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, Asselah T, Jonsson JR, Smedile A, Terrault N, Pazienza V, Giordani MT, Giostra E, Sonzogni A, Ruggiero G, Marcellin P, Powell EE, George J, Negro F. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. *Gastroenterology* 2006; **130**: 1636-1642 [PMID: 16697727 DOI: 10.1053/j.gastro.2006.03.014]

33 **Rodriguez-Torres M**, Govindarajan S, Diago M, Morgan T, Anand B, Barange K, Suter F, Lin A, Hooper G, Shiffman M. Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks. *Liver Int* 2009; **29**: 237-241 [PMID: 18710427 DOI: 10.1111/j.1478-3231.2008.01859.x]

34 **Kumar D**, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. *Hepatology* 2002; **36**: 1266-1272 [PMID: 12395339 DOI: 10.1053/jhep.2002.36370]

35 **Poynard T**, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. *Hepatology* 2003; **38**: 75-85 [PMID: 12829989 DOI: 10.1053/jhep.2003.50267]

36 **Castéra L**, Hézode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM, Dhumeaux D. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. *Gut* 2004; **53**: 420-424 [PMID: 14960527]

37 **Sharma P**, Balan V, Hernandez J, Rosati M, Williams J, Rodriguez-Luna H, Schwartz J, Harrison E, Anderson M, Byrne T, Vargas HE, Douglas DD, Rakela J. Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors? *Dig Dis Sci* 2004; **49**: 25-29 [PMID: 14992430]

38 **Serfaty L**, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. *J Hepatol* 2001; **34**: 428-434 [PMID: 11322205]

39 **Siagris D**, Christofidou M, Theocharis GJ, Pagoni N, Papadimitriou C, Lekkou A, Thomopoulos K, Starakis I, Tsamandas AC, Labropoulou-Karatza C. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. *J Viral Hepat* 2006; **13**: 56-61 [PMID: 16364083 DOI: 10.1111/j.1365-2893.2005.00655.x]

40 **Westin J**, Nordlinder H, Lagging M, Norkrans G, Wejstål R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. *J Hepatol* 2002; **37**: 837-842 [PMID: 12445426]

41 **Bochud PY**, Cai T, Overbeck K, Bochud M, Dufour JF, Müllhaupt B, Borovicka J, Heim M, Moradpour D, Cerny A, Malinverni R, Francioli P, Negro F. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. *J Hepatol* 2009; **51**: 655-666 [PMID: 19665246 DOI: 10.1016/j.jhep.2009.05.016]

42 **Probst A**, Dang T, Bochud M, Egger M, Negro F, Bochud PY. Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis. *J Viral Hepat* 2011; **18**: 745-759 [PMID: 21992794 DOI: 10.1111/j.1365-2893.2011.01481.x]

43 **Rubbia-Brandt L**, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, Carlotto A, Bozzola L, Smedile A, Negro F. Steatosis affects chronic hepatitis C progression in a genotype specific way. *Gut* 2004; **53**: 406-412 [PMID: 14960525]

44 **Asselah T**, Boyer N, Guimont MC, Cazals-Hatem D, Tubach F, Nahon K, Daïkha H, Vidaud D, Martinot M, Vidaud M, Degott C, Valla D, Marcellin P. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. *Gut* 2003; **52**: 1638-1643 [PMID: 14570735]

45 **Bugianesi E**, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, George J. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. *Hepatology* 2006; **44**: 1648-1655 [PMID: 17133473 DOI: 10.1002/hep.21429]

46 **Del Campo JA**, Romero-Gómez M. Steatosis and insulin resistance in hepatitis C: a way out for the virus? *World J Gastroenterol* 2009; **15**: 5014-5019 [PMID: 19859993]

47 **Naing C**, Mak JW, Wai N, Maung M. Diabetes and infections-hepatitis C: is there type 2 diabetes excess in hepatitis C infection? *Curr Diab Rep* 2013; **13**: 428-434 [PMID: 23463119 DOI: 10.1007/s11892-013-0370-3]

48 **Petta S**, Rosso C, Leung R, Abate ML, Booth D, Salomone F, Gambino R, Rizzetto M, Caviglia P, Smedile A, Grimaudo S, Cammà C, Craxì A, George J, Bugianesi E. Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. *Clin Gastroenterol Hepatol* 2013; **11**: 311-7.e1 [PMID: 23220171 DOI: 10.1016/j.cgh.2012.11.022]

49 **Thompson AJ**, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, Flisiak R, Pianko S, Diago M, Arora S, Foster GR, Torbenson M, Benhamou Y, Nelson DR, Sulkowski MS, Zeuzem S, Pulkstenis E, Subramanian GM, McHutchison JG. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. *Gut* 2012; **61**: 128-134 [PMID: 21873466 DOI: 10.1136/gut.2010.236158]

50 **Larsen C**, Bousquet V, Delarocque-Astagneau E, Pioche C, Roudot-Thoraval F; HCV Surveillance Steering Committee; HCV Surveillance Group, Desenclos JC. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France. *J Med Virol* 2010; **82**: 1647-1654 [PMID: 20827760 DOI: 10.1002/jmv.21850]

51 **Nkontchou G**, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, Roulot D, Ganne-Carrie N, Grando-Lemaire V, Trinchet JC, Gordien E, Vicaut E, Baghad I, Beaugrand M. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. *J Viral Hepat* 2011; **18**: e516-e522 [PMID: 21914071 DOI: 10.1111/j.1365-2893.2011.01441.x]

52 **Idrees M**, Rafique S, Rehman I, Akbar H, Yousaf MZ, Butt S, Awan Z, Manzoor S, Akram M, Aftab M, Khubaib B, Riazuddin S. Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. *World J Gastroenterol* 2009; **15**: 5080-5085 [PMID: 19860002]

53 **McCombs J**, Matsuda T, Tonnu-Mihara I, Saab S, Hines P, L'italien G, Juday T, Yuan Y. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. *JAMA Intern Med* 2014; **174**: 204-212 [PMID: 24193887 DOI: 10.1001/jamainternmed.2013.12505]

54 **Grassi A**, Ballardini G. Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem. *World J Gastroenterol* 2014; **20**: 11095-11115 [PMID: 25170198 DOI: 10.3748/wjg.v20.i32.11095]

55 **Cacoub P**, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. *Dig Liver Dis* 2014; **46** Suppl 5: S165-S173 [PMID: 25458776 DOI: 10.1016/j.dld.2014.10.005]

56 **Aziz H**, Raza A, Waheed Y, Gill U, Gill ML. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients. *Int J Infect Dis* 2012; **16**: e597-e602 [PMID: 22658873 DOI: 10.1016/j.ijid.2012.03.012]

57 **El-Shamy A**, Hotta H. Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview. *World J Gastroenterol* 2014; **20**: 7555-7569 [PMID: 24976696 DOI: 10.3748/wjg.v20.i24.7555]

58 **Moreau I**, Levis J, Crosbie O, Kenny-Walsh E, Fanning LJ. Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a. *Virol J* 2008; **5**: 78 [PMID: 18613968 DOI: 10.1186/1743-422X-5-78]

59 **ElHefnawi MM**, Zada S, El-Azab IA. Prediction of prognostic biomarkers for interferon-based therapy to hepatitis C virus patients: a meta-analysis of the NS5A protein in subtypes 1a, 1b, and 3a. *Virol J* 2010; **7**: 130 [PMID: 20550652 DOI: 10.1186/1743-422X-7-130]

60 **Kumthip K**, Pantip C, Chusri P, Thongsawat S, O'Brien A, Nelson KE, Maneekarn N. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy. *J Viral Hepat* 2011; **18**: e117-e125 [PMID: 20955493 DOI: 10.1111/j.1365-2893.2010.01379.x]

61 **El-Shamy A**, Shoji I, El-Akel W, Bilasy SE, Deng L, El-Raziky M, Jiang DP, Esmat G, Hotta H. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. *J Clin Microbiol* 2012; **50**: 3886-3892 [PMID: 22993188 DOI: 10.1128/JCM.02109-12]

62 **Mansoor A**, Ali L, Sabah NU, Hashmi AH, Khan MH, Kazmi SA, Ahmad N, Siddiqi S, Khan KM. Study of PKRBD in HCV genotype 3a infected patients in response to interferon therapy in Pakistani population. *Virol J* 2013; **10**: 352 [PMID: 24321105 DOI: 10.1186/1743-422X-10-352]

63 **Aghemo A**, Rumi MG, Soffredini R, D'Ambrosio R, Ronchi G, Del Ninno E, Gallus S, Colombo M. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. *Antivir Ther* 2006; **11**: 797-802 [PMID: 17310824]

64 **Shoeb D**, Rowe IA, Freshwater D, Mutimer D, Brown A, Moreea S, Sood R, Marley R, Sabin CA, Foster GR. Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse. *Eur J Gastroenterol Hepatol* 2011; **23**: 747-753 [PMID: 21691208 DOI: 10.1097/MEG.0b013e3283488aba]

65 **Shoeb D**, Dearden J, Weatherall A, Bargery C, Moreea S, Alam S, White E, Vila X, Freshwater D, Ryder S, Mills PR, Alexander GJ, Forton D, Foster GR. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial. *J Hepatol* 2014; **60**: 699-705 [PMID: 24291239 DOI: 10.1016/j.jhep.2013.11.011]

66 **Powis J**, Peltekian KM, Lee SS, Sherman M, Bain VG, Cooper C, Krajden M, Deschenes M, Balshaw RF, Heathcote EJ, Yoshida EM; Canadian Pegasys Study Group. Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. *J Viral Hepat* 2008; **15**: 52-57 [PMID: 18088245 DOI: 10.1111/j.1365-2893.2007.00889.x]

67 **Aghemo A**, Rumi MG, Monico S, Prati GM, D'Ambrosio R, Donato MF, Colombo M. The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. *Antivir Ther* 2009; **14**: 577-584 [PMID: 19578243]

68 **Harrison SA**, Brunt EM, Qazi RA, Oliver DA, Neuschwander-Tetri BA, Di Bisceglie AM, Bacon BR. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. *Clin Gastroenterol Hepatol* 2005; **3**: 604-609 [PMID: 15952103]

69 **Zeuzem S**, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. *J Hepatol* 2004; **40**: 993-999 [PMID: 15158341 DOI: 10.1016/j.jhep.2004.02.007]

70 **Shah SR**, Patel K, Marcellin P, Foster GR, Manns M, Kottilil S, Healey L, Pulkstenis E, Subramanian GM, McHutchison JG, Sulkowski MS, Zeuzem S, Nelson DR. Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. *Clin Gastroenterol Hepatol* 2011; **9**: 688-693 [PMID: 21640198 DOI: 10.1016/j.cgh.2011.04.029]

71 **Marciano S**, Borzi SM, Dirchwolf M, Ridruejo E, Mendizabal M, Bessone F, Sirotinsky ME, Giunta DH, Trinks J, Olivera PA, Galdame OA, Silva MO, Fainboim HA, Gadano AC. Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3. *World J Hepatol* 2015; **7**: 703-709 [PMID: 25866607 DOI: 10.4254/wjh.v7.i4.703]

72 **Pattullo V**, Heathcote EJ, Wong DK. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. *Hepatol Int* 2010; **4**: 723-731 [PMID: 21286343 DOI: 10.1007/s12072-010-9207-1]

73 **Vutien P**, Nguyen NH, Trinh HN, Li J, Garcia RT, Garcia G, Nguyen KK, Nguyen HA, Levitt BS, Keeffe EB, Nguyen MH. Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C. *Am J Gastroenterol* 2010; **105**: 1110-1115 [PMID: 19904247 DOI: 10.1038/ajg.2009.635]

74 **Freshwater DA**, O'Donnell K, Mutimer DJ. Inferior response of Asian vs non-Asian hepatitis C genotype 3 infection to combination antiviral therapy. *J Viral Hepat* 2008; **15**: 115-119 [PMID: 18184194 DOI: 10.1111/j.1365-2893.2007.00899.x]

75 **Matsuura K**, Watanabe T, Tanaka Y. Role of IL28B for chronic hepatitis C treatment toward personalized medicine. *J Gastroenterol Hepatol* 2014; **29**: 241-249 [PMID: 24325405 DOI: 10.1111/jgh.12475]

76 **Stättermayer AF**, Scherzer T, Beinhardt S, Rutter K, Hofer H, Ferenci P. Review article: genetic factors that modify the outcome of viral hepatitis. *Aliment Pharmacol Ther* 2014; **39**: 1059-1070 [PMID: 24654629 DOI: 10.1111/apt.12717]

77 **Cariani E**, Roli L, Missale G, Villa E, Ferrari C, Trenti T. Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. *Pharmacogenomics J* 2015; Epub ahead of print [PMID: 25918016 DOI: 10.1038/tpj.2015.28]

78 **Firdaus R**, Biswas A, Saha K, Mukherjee A, Chaudhuri S, Chandra A, Konar A, Sadhukhan PC. Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients. *PLoS One* 2014; **9**: e99126 [PMID: 24914551 DOI: 10.1371/journal.pone.0099126]

79 **Holmes JA**, Congiu M, Bonanzinga S, Sandhu MK, Kia YH, Bell SJ, Nguyen T, Iser DM, Visvanathan K, Sievert W, Bowden DS, Desmond PV, Thompson AJ. The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3. *Aliment Pharmacol Ther* 2015; **42**: 296-306 [PMID: 26032235 DOI: 10.1111/apt.13263]

80 **Prokunina-Olsson L**, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. *Nat Genet* 2013; **45**: 164-171 [PMID: 23291588 DOI: 10.1038/ng.2521]

81 **Robinson MW**, Aranday-Cortes E, Gatherer D, Swann R, Liefhebber JM, Filipe AD, Sigruener A, Barclay ST, Mills PR, Patel AH, McLauchlan J. Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection. *Liver Int* 2015; Epub ahead of print [PMID: 25800823 DOI: 10.1111/liv.12830]

82 **Robinson MW**, Swann R, Sigruener A, Barclay ST, Mills PR, McLauchlan J, Patel AH. Elevated interferon-stimulated gene transcription in peripheral blood mononuclear cells occurs in patients infected with genotype 1 but not genotype 3 hepatitis C virus. *J Viral Hepat* 2015; **22**: 384-390 [PMID: 25200131 DOI: 10.1111/jvh.12310]

83 **Faisal N**, Mumtaz K, Marquez M, Renner EL, Lilly LB. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation. *Hepatol Int* 2015; **9**: 76-83 [PMID: 25788382 DOI: 10.1007/s12072-014-9589-6]

84 **Knapstein J**, Wörns MA, Galle PR, Zimmermann T. Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report. *J Med Case Rep* 2014; **8**: 257 [PMID: 25047566 DOI: 10.1186/1752-1947-8-257]

85 **Selic Kurincic T**, Lesnicar G, Poljak M, Meglic Volkar J, Rajter M, Prah J, Baklan Z, Kotar T, Maticic M. Impact of added fluvastatin to standard-of-care treatment on sustained virological response in naïve chronic hepatitis C Patients infected with genotypes 1 and 3. *Intervirology* 2014; **57**: 23-30 [PMID: 24080608 DOI: 10.1159/000354541]

86 **Pandya P**, Rzouq F, Oni O. Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases. *Clin Res Hepatol Gastroenterol* 2015; Epub ahead of print [PMID: 25835493 DOI: 10.1016/j.clinre.2015.02.005]

87 **Russo MW**, Fried MW. Side effects of therapy for chronic hepatitis C. *Gastroenterology* 2003; **124**: 1711-1719 [PMID: 12761728]

88 **Negro F**. Adverse effects of drugs in the treatment of viral hepatitis. *Best Pract Res Clin Gastroenterol* 2010; **24**: 183-192 [PMID: 20227031 DOI: 10.1016/j.bpg.2009.10.012]

89 **Foster GR**, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. *Gastroenterology* 2011; **141**: 881-889.e1 [PMID: 21699786 DOI: 10.1053/j.gastro.2011.05.046]

90 **Pawlotsky JM**. New hepatitis C therapies: the toolbox, strategies, and challenges. *Gastroenterology* 2014; **146**: 1176-1192 [PMID: 24631495 DOI: 10.1053/j.gastro.2014.03.003]

91 **Lenz O**, Vijgen L, Berke JM, Cummings MD, Fevery B, Peeters M, De Smedt G, Moreno C, Picchio G. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). *J Hepatol* 2013; **58**: 445-451 [PMID: 23142061 DOI: 10.1016/j.jhep.2012.10.028]

92 **Moreno C**, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, Lenz O, Peeters M, Sekar V, De Smedt G. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. *J Hepatol* 2012; **56**: 1247-1253 [PMID: 22326470 DOI: 10.1016/j.jhep.2011.12.033]

93 **Gentile I**, Buonomo AR, Borgia F, Zappulo E, Castaldo G, Borgia G. MK-5172 Epub ahead of print a second-generation protease inhibitor for the treatment of hepatitis C virus infection. *Expert Opin Investig Drugs* 2014; **23**: 719-728 [PMID: 24666106 DOI: 10.1517/13543784.2014.902049]

94 **Clark VC**, Peter JA, Nelson DR. New therapeutic strategies in HCV: second-generation protease inhibitors. *Liver Int* 2013; **33** Suppl 1: 80-84 [PMID: 23286850 DOI: 10.1111/liv.12061]

95 **Bunchorntavakul C**, Reddy KR. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. *Aliment Pharmacol Ther* 2015; **42**: 258-272 [PMID: 26014906 DOI: 10.1111/apt.13264]

96 **Noell BC**, Besur SV, deLemos AS. Changing the face of hepatitis C management - the design and development of sofosbuvir. *Drug Des Devel Ther* 2015; **9**: 2367-2374 [PMID: 25987834 DOI: 10.2147/DDDT.S65255]

97 **Lawitz E**, Poordad F, Brainard DM, Hyland RH, An D, Dvory-Sobol H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. *Hepatology* 2015; **61**: 769-775 [PMID: 25322962 DOI: 10.1002/hep.27567]

98 **Dore GJ**, Lawitz E, Hézode C, Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A, Brunetto MR, Zaltron S, Strasser SI, Weis N, Ghesquiere W, Lee SS, Larrey D, Pol S, Harley H, George J, Fung SK, de Lédinghen V, Hagens P, McPhee F, Hernandez D, Cohen D, Cooney E, Noviello S, Hughes EA. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. *Gastroenterology* 2015; **148**: 355-366.e1 [PMID: 25311593 DOI: 10.1053/j.gastro.2014.10.007]

99 **Jacobson IM**, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. *N Engl J Med* 2013; **368**: 1867-1877 [PMID: 23607593 DOI: 10.1056/NEJMoa1214854]

100 **Zeuzem S**, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. *N Engl J Med* 2014; **370**: 1993-2001 [PMID: 24795201 DOI: 10.1056/NEJMoa1316145]

101 **Nelson DR**, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. *Hepatology* 2015; **61**: 1127-1135 [PMID: 25614962 DOI: 10.1002/hep.27726]

102 **Hezode C**, De Ledinghen V, Fontaine H, Zoulim F, Lebray P, Boyer N, Larrey D, Silvain C, Botta-Fridlund D, Leroy V, Bourliere M, D’Alteroche L. LP05 Epub ahead of print Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use program. *J Hepatol* 2015; **62**, Supplement 2(0): S265-S266 [DOI: 10.1016/S0168-8278(15)30159-8]

103 **Keating GM**. Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. *Drugs* 2015; **75**: 675-685 [PMID: 25837989 DOI: 10.1007/s40265-015-0381-2]

104 **Gane EJ**, Hyland RH, An D, Pang PS, Symonds WT, McHutchison JG, Stedman CA. O6 Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience. *J Hepatol* 2014; **60** (1, Supplement): S3-S4 [DOI: 10.1016/S0168-8278(14)60008-8]

105 **Hernandez D**, Zhou N, Ueland J, Monikowski A, McPhee F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. *J Clin Virol* 2013; **57**: 13-18 [PMID: 23384816 DOI: 10.1016/j.jcv.2012.12.020]

106 **Gane E**, Nahass R, Luketic V, Hwang P, Robertson M, Wahl J, Barr E, Haber B. P0776 Epub ahead of print Efficacy of 12 or 18 weeks of grazoprevir plus elbasvir with ribavirin in treatment-naive, noncirrhotic HCV genotype 3-infected patients. *J Hepatol* 2015; **62**, Supplement 2(0): S621 [DOI: 10.1016/S0168-8278(15)30979-X]

107 **Everson GT**, Tran TT, Towner WJ, Davis MN, Wyles D, Nahass R, McNally J, Brainard DM, Han L, Doehle B, Mogalian E, Symonds WT, et al. O111 Safety and efficacy of treatment with the interferon-free, ribavirin-free combination of sofosbuvir gs-5816 for 12 weeks in treatment naive patients with genotype 1–6 hcv infection. *J Hepatol* 2014; **60** (1, Supplement): S46 [DOI: 10.1016/S0168-8278(14)60113-6]

108 **Doehle BP**, Svarovskaia ES, Chodavarapu K, McNally J, Pianko S, Roberts SK, Brainard DM, Miller MD, Mo H. P0893 Epub ahead of print Resistance analysis of treatment-experienced genotype 1 and 3 HCV infected patients treated with sofosbuvir in combination with GS-5816 /− ribavirin for 12 weeks. *J Hepatol* 2015; **62**, Supplement 2(0): S678 [DOI: 10.1016/S0168-8278(15)31096-5]

109 **Roingeard P**. Hepatitis C virus diversity and hepatic steatosis. *J Viral Hepat* 2013; **20**: 77-84 [PMID: 23301542 DOI: 10.1111/jvh.12035]

110 **Goossens N**, Negro F. Is genotype 3 of the hepatitis C virus the new villain? *Hepatology* 2014; **59**: 2403-2412 [PMID: 24155107 DOI: 10.1002/hep.26905]

111 **Mirandola S**, Realdon S, Iqbal J, Gerotto M, Dal Pero F, Bortoletto G, Marcolongo M, Vario A, Datz C, Hussain MM, Alberti A. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. *Gastroenterology* 2006; **130**: 1661-1669 [PMID: 16697730 DOI: 10.1053/j.gastro.2006.02.035]

112 **de Gottardi A**, Pazienza V, Pugnale P, Bruttin F, Rubbia-Brandt L, Juge-Aubry CE, Meier CA, Hadengue A, Negro F. Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. *Aliment Pharmacol Ther* 2006; **23**: 107-114 [PMID: 16393287 DOI: 10.1111/j.1365-2036.2006.02729.x]

113 **Hofer H**, Bankl HC, Wrba F, Steindl-Munda P, Peck-Radosavljevic M, Osterreicher C, Mueller C, Gangl A, Ferenci P. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. *Am J Gastroenterol* 2002; **97**: 2880-2885 [PMID: 12425563 DOI: 10.1111/j.1572-0241.2002.07056.x]

114 **Clément S**, Peyrou M, Sanchez-Pareja A, Bourgoin L, Ramadori P, Suter D, Vinciguerra M, Guilloux K, Pascarella S, Rubbia-Brandt L, Negro F, Foti M. Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets. *Hepatology* 2011; **54**: 38-49 [PMID: 21465511 DOI: 10.1002/hep.24340]

115 **Abid K**, Pazienza V, de Gottardi A, Rubbia-Brandt L, Conne B, Pugnale P, Rossi C, Mangia A, Negro F. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. *J Hepatol* 2005; **42**: 744-751 [PMID: 15826725 DOI: 10.1016/j.jhep.2004.12.034]

116 **Loizides-Mangold U**, Clément S, Alfonso-Garcia A, Branche E, Conzelmann S, Parisot C, Potma EO, Riezman H, Negro F. HCV 3a core protein increases lipid droplet cholesteryl ester content via a mechanism dependent on sphingolipid biosynthesis. *PLoS One* 2014; **9**: e115309 [PMID: 25522003 DOI: 10.1371/journal.pone.0115309]

117 **Gondeau C**, Pichard-Garcia L, Maurel P. Cellular models for the screening and development of anti-hepatitis C virus agents. *Pharmacol Ther* 2009; **124**: 1-22 [PMID: 19555718 DOI: 10.1016/j.pharmthera.2009.05.010]

118 **Gondeau C**, Briolotti P, Razafy F, Duret C, Rubbo PA, Helle F, Rème T, Ripault MP, Ducos J, Fabre JM, Ramos J, Pécheur EI, Larrey D, Maurel P, Daujat-Chavanieu M. In vitro infection of primary human hepatocytes by HCV-positive sera: insights on a highly relevant model. *Gut* 2014; **63**: 1490-1500 [PMID: 24153249 DOI: 10.1136/gutjnl-2013-304623]

119 **Saeed M**, Gondeau C, Hmwe S, Yokokawa H, Date T, Suzuki T, Kato T, Maurel P, Wakita T. Replication of hepatitis C virus genotype 3a in cultured cells. *Gastroenterology* 2013; **144**: 56-58.e7 [PMID: 22999961 DOI: 10.1053/j.gastro.2012.09.017]

120 **Kim S**, Date T, Yokokawa H, Kono T, Aizaki H, Maurel P, Gondeau C, Wakita T. Development of hepatitis C virus genotype 3a cell culture system. *Hepatology* 2014; **60**: 1838-1850 [PMID: 24797787 DOI: 10.1002/hep.27197]

121 **von Schaewen M**, Ploss A. Murine models of hepatitis C: what can we look forward to? *Antiviral Res* 2014; **104**: 15-22 [PMID: 24462693 DOI: 10.1016/j.antiviral.2014.01.007]

122 **Ramanan V**, Scull MA, Sheahan TP, Rice CM, Bhatia SN. New Methods in Tissue Engineering: Improved Models for Viral Infection. *Annu Rev Virol* 2014; **1**: 475-499 [PMID: 25893203 DOI: 10.1146/annurev-virology-031413-085437]

**P-Reviewer:** Grassi G, Kondo Y **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 Reported prevalence of hepatitis C virus genotype 3**

|  |  |  |  |
| --- | --- | --- | --- |
| Country, Region | Viremic population (000) | Genotype 3 prevalence | Ref. |
| Asia |  |  |  |
| India | 6026 (3157-7174) | 54.4% | [[8](#_ENREF_8)] |
|  | 8666 (5150-15449) | 64.0% | [[14](#_ENREF_14)] |
| Malaysia | 237 (47-1216) | 58.6% | [[8](#_ENREF_8)] |
| Pakistan | 7039 (1728-10,524) | 79.0% | [[8](#_ENREF_8)] |
| Thailand | 925 (633-1259) | 44.2% | [[8](#_ENREF_8)] |
| Thailand, North |  | 23%/16% (3a/3b) | [[17](#_ENREF_17)] |
| Thailand, South |  | 38%/14% (3a/3b) | [[17](#_ENREF_17)] |
|  |  |  |  |
| Europe, Western |  |  |  |
| Denmark | 21 (14-21) | 43.0% | [[8](#_ENREF_8)] |
| Finland | 22 (16-27) | 46.0% | [[8](#_ENREF_8)] [[14](#_ENREF_14)] |
| Norway | 29 (25-37) | 28.1% | [[8](#_ENREF_8)] |
|  | 22 (18-28) | 50.0% | [[14](#_ENREF_14)] |
| United Kingdom | 210 (125-428) | 43.8% | [[8](#_ENREF_8)] |
|  |  |  |  |
| Middle East |  |  |  |
| Turkey | 434 (274-959) | 4.9% | [[8](#_ENREF_8)] |
| Turkey, province of Kahramanmaras |  | 46.0% | [[16](#_ENREF_16)] |
|  |  |  |  |
| Australasia |  |  |  |
| Australia | 234 (169-260) | 36.8% | [[8](#_ENREF_8)] |
| New Zealand | 50 (27-72) | 35.0% | [[8](#_ENREF_8)] [[14](#_ENREF_14)] |

**Table 2 Factors associated with poor response to pegylated interferon  /RVB in hepatitis C virus GT-3- infected patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Factors | Study design | Number of patients | Characteristics | Ref. | Comments |
| Viral factors |  |  |  |  |  |
| High baseline viral load (> 8 x 105 UI/mL) | Prospective | 426 (all GT-3) | 223 patients with viral load > 8 x 105 UI/mL | [[56](#_ENREF_56)] | Combined with non-RVR |
| High baseline viral load (> 6 x 105 UI/mL) | Retrospective | 107 (all GT-3) | 45 non-SVR/62 SVR | [[71](#_ENREF_71)] | Combined with advanced fibrosis |
| High baseline quasi-species complexity and diversity | Retrospective | 10 (all GT-3) |  | [[58](#_ENREF_58)] |  |
| Mutations in NS5A | Prospective | 49 (all GT-3) | 25 non-SVR/24 SVR | [[62](#_ENREF_62)] | Significant mutations at positions 2309 (Ala to Ser) and 2326 (Gly to Ala) |
|  |  |  |  |  |  |
| Host factors |  |  |  |  |  |
| Fibrosis/Cirrhosis | Prospective | 91 (all GT-3) | 17 cirrhotic/74 non-cirrhotic | [[63](#_ENREF_63)] | Also associated with increased risk of post-treatment relapse |
|  | Retrospective | 604 (all GT-3) | 145 cirrhotic/459 non-cirrhotic | [[64](#_ENREF_64)] | Response not affected by ethnicity |
|  | Retrospective | 180 | 108 GT-3/72 GT-2 | [[66](#_ENREF_66)] | Lack of SVR associated with fibrosis and GT-3 |
|  | Retrospective | 107(all GT-3) | 45 non-SVR/62 SVR | [[71](#_ENREF_71)] | Combined with high baseline viral load |
|  |  |  |  |  |  |
| Steatosis | Prospective | 224 | 182 GT-3/42 GT-2 | [[69](#_ENREF_69)] | Lower SVR in GT-3 |
|  | Retrospective | 932 | 505 GT-3/427 GT-2 | [[70](#_ENREF_70)] | Associated with higher relapse rates in GT-3 patients who had RVR |
| Ethnicity | Retrospective | 103 | 66 Caucasians/38 Asians | [[74](#_ENREF_74)] | Poor response could reflect more advanced liver disease at baseline in Asian patients |
|  | Retrospective | 604 (all GT-3) | 305 non-Asians/299 South Asians | [[64](#_ENREF_64)] | No correlation between ethnicity and treatment relapse |
| *IFNL3* gene polymorphisms | Retrospective | 107 (all GT-3) | 45 non-SVR/62 SVR | [[71](#_ENREF_71)] | No correlation between *IFNL3* polymorphisms and SVR |
|  | Prospective | 293 HCV RNA- positive | 65.87% GT-3/32.08% GT-1 | [[78](#_ENREF_78)] | CC and TT alleles strongly associated with SVR in GT-3 patients |
| Intrahepatic ISG15 expression/*IFNL4* gene polymorphisms | Retrospective | 92 | 36 GT-3/56 GT-1 | [[79](#_ENREF_79)] | In GT-3, low ISG15 expression and good-responder *IFNL4* genotype associated with high SVR rates |

GT: Genotype; SVR: Sustained virologic response; RVR: Rapid virologic response; NS5A: Non-structural 5A protein; IFNL: Interferon lambda; ISG: Interferon-stimulated gene; HCV: hepatitis C virus.

**Table 3 Overview of direct-acting antiviral-containing treatments for hepatitis C virus GT-3-infected patients**

|  |  |  |  |
| --- | --- | --- | --- |
| Drug combination | Recommendations1 | Duration | Ref. |
| IFN-containing treatment |  |  |  |
| PEG-IFN/RBV and SOF | For treatment-experienced patients, with or without cirrhosis | 12 wk | [[97](#_ENREF_97)] |
|  |  |  |  |
| PEG-IFN/RBV and DCV | Not yet recommended | 12 or 16 wk | [[98](#_ENREF_98)] |
|  |  |  |  |
| IFN-free treatment |  |  |  |
| SOF and RBV | Suboptimal in treatment-experienced cirrhotic patients | 24 wk | [[99](#_ENREF_99),[100](#_ENREF_100)] |
|  |  |  |  |
| SOF and DCV | For patients without cirrhosis | 12 wk | [[101](#_ENREF_101)] |
|  |  |  |  |
| SOF/DCV and RBV | For treatment-naive and treatment-experienced patients with cirrhosis | 24 wk | [[102](#_ENREF_102)] |
|  |  |  |  |
|  |  |  |  |
| SOF/ledipasvir  (single-tablet regimen) | Not yet recommended | 12 wk | [[104](#_ENREF_104)] |
|  |  |  |  |
| Promising therapeutic option |  |  |  |
| GS-5816/SOF ± RBV | Under evaluation | 12 wk | [[107](#_ENREF_107),[108](#_ENREF_108)] |

1According to the EASL Clinical Practice Guidelines in April 2015[[10](#_ENREF_10)].